论文信息 - Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL), - 字舞流文

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Scott E. Smith | R. Advani | N. Bartlett | O. O’Connor | A. Forero-Torres | M. Fanale | R. Olshefski | J. Matous | A. Gopal | L. Grove | R. Berryman | Robert Chen